Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea

Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS ...

Canada Just Got Generic Ozempic. Americans Shouldn’t Hold Their Breath

The availability of generic drugs is expected to have a positive impact in Canada, including potential cost savings for ...

FDA announces pilot program featuring real-time clinical trial monitoring

Dr. Marty Makary, the FDA’s commissioner, said the program targets “dead time,” or about half the time between the launch of ...
PharmExec

Teva Enters $900 Million Agreement to Acquire Emalex

Teva Pharmaceutical Industries agreed to acquire Emalex Biosciences in a deal valued at $900 million. The acquisition centers ...
Opinion

Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders

Urges Stockholders to Vote "FOR" Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today Strongly Opposes the Election of Each of DOMA's Underqualified Nominees BRISBANE, Calif., April 28, 202 ...
C&EN

Astellas’s R&D head talks strategy ahead of looming patent cliff

Astellas Pharma chief R&D officer Tadaaki Taniguchi at the Astellas Life Sciences Center in Cambridge, Massachusetts. Credit: ...
Trade Brains on MSN

Rs14 pharma stock targeting 30% CAGR and 300% capacity expansion - a future multibagger?

India, April 29 -- A micro-pharma stock trading at Rs. 13.80 has come into focus after the company outlined an aggressive growth plan involving around 30 percent revenue CAGR over the next three years ...